Trial reportPsychopharmacology2009
Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers.
Trial report in Psychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 69 citations in OpenAlex.
- Effects of 28-day simvastatin administration on emotional processing, reward learning, working memory, and salivary cortisol in healthy participants at-risk for depression: OxSTEP, an online experimental medicine trial.Psychological medicine · 2025Trial
- Effects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers.Psychopharmacology · 2014Trial
- Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report.Human psychopharmacology · 2014Trial
- Pre-encoding administration of amphetamine or THC preferentially modulates emotional memory in humans.Psychopharmacology · 2013Trial
- Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantine.Journal of psychopharmacology (Oxford, England) · 2012Trial
- Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images.Journal of psychopharmacology (Oxford, England) · 2012Trial
- Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.Schizophrenia research · 2012Trial
- Probiotics reduce negative mood over time: the value of daily self-reports in detecting effects.Npj mental health research · 2025Article
- Neuropsychological Effects of Antidepressants: Translational Studies.Current topics in behavioral neurosciences · 2024Review
- Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment.Psychopharmacology · 2021Review
- Meet Your Stress Management Professionals: The Endocannabinoids.Trends in molecular medicine · 2020Review
- Curcumin in Depression: Potential Mechanisms of Action and Current Evidence-A Narrative Review.Frontiers in psychiatry · 2020Review
- Druggable Targets in Endocannabinoid Signaling.Advances in experimental medicine and biology · 2020Review
- An endocannabinoid receptor polymorphism modulates affective processing under stress.Social cognitive and affective neuroscience · 2018Article
- Using the affective bias test to predict drug-induced negative affect: implications for drug safety.British journal of pharmacology · 2017Article
- Article
- Changes in the Brain Endocannabinoid System in Rat Models of Depression.Neurotoxicity research · 2017Article
- Interactions of Cannabinoids With Biochemical Substrates.Substance abuse : research and treatment · 2017Review
- Neural mechanisms of sensitivity to peer information in young adult cannabis users.Cognitive, affective & behavioral neuroscience · 2016Article
- Neurobiological Interactions Between Stress and the Endocannabinoid System.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundEmotional processing measures are sensitive to acute administration of clinically useful antidepressant drugs. We wished to test the hypothesis that these models would also be able to detect agents likely to cause depression as an adverse effect. The anti-obesity drug and cannabinoid type 1 receptor antagonist, rimonabant, is associated with significant rates of depression and anxiety in clinical use. MATERIALS AND
methodsThirty healthy adult volunteers were randomly assigned to receive a single dose of rimonabant (20 mg) or lactose placebo in a double-blind, between-groups design. Three hours after medication administration, subjects undertook an emotional processing test battery including facial emotion recognition, emotional word attentional dot probe, self-relevant word classification, emotional and declarative memory and the emotion-potentiated acoustic startle response. Subjective state was assessed via self-report measures.
resultsA single dose of rimonabant did not alter subjective mood. However, rimonabant selectively reduced incidental recall of positive self-relevant adjectives, an effect contrary to that seen following the administration of antidepressants. There were no effects of rimonabant on the other measures of emotional processing.
conclusionsThese results suggest that a single dose of rimonabant decreases positive emotional memory in the absence of changes in subjective state. Further studies are required to examine whether rimonabant might produce a wider range of negative emotional biases with repeated treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.